Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

CB1 cannabinoid receptors mediate anxiolytic effects: convergent genetic and pharmacological evidence with CB1-specific agents

Haller, J.a; Varga, B.a; Ledent, C.b; Freund, T. F.a

doi: 10.1097/01.fbp.0000135704.56422.40

Cannabinoids are known to modulate GABAergic and glutamatergic transmission in cortical areas, the former via CB1 and the latter via a novel receptor. Pharmacological data demonstrate that several widely used cannabinoid ligands bind to both receptors, which may explain the inconsistencies in their behavioural effects. Earlier we showed that the cannabinoid antagonist SR-141716A affected behaviour in both CB1 knockout and wild-type animals, and its effect (anxiolysis) was different from that of CB1 gene disruption (anxiogenesis). In the present experiments, we studied the effects of the CB1 antagonist AM-251, and the cannabinoid agonist WIN-55,212-2 in wild-type as well as in CB1 knockout mice. CB1 knockout mice showed higher scores of anxiety-like behaviour than the wild-type animals in the elevated plus-maze. Selective blockade of CB1 receptors by AM-251 (0.3, 1 and 3 mg/kg) increased anxiety-like behaviour dose-dependently in the wild-type mice but had no effect in the knockouts. In wild types, the cannabinoid agonist WIN-55,212-2 (1 and 3 mg/kg) caused a decrease in anxiety-like behaviour, which was abolished by the CB1-selective antagonist AM-251 (3 mg/kg). The same agonist did not change plus-maze behaviour in CB1 knockout animals. These data demonstrate at the behavioural level that AM-251 and, at low concentrations, WIN-55,212-2, are selective ligands of the CB1 cannabinoid receptor in mice. Our studies on the behavioural effects of the cannabinoid antagonist SR-141716A and the CB1 antagonist AM-251 show that the CB1 and the novel cannabinoid receptor mediate anxiolytic and anxiogenic effects, respectively. This suggests that agonists of the former, or antagonists of the latter, are promising new compounds in the pharmacotherapy of anxiety.

aInstitute of Experimental Medicine, Budapest, Hungary

bIRIBHN, Université libre de Bruxelles, Brussels, Belgium

Sponsorship: This work was supported by Philip Morris, NIH (MH54671), and OTKA 32251 grants to T.F.F., as well as OMFB BIO-00142/2001, and ETT 286/2001 grants to J.H.

Correspondence and requests for reprints to J. Haller, Ph.D., Institute of Experimental Medicine, 1450 Budapest, P.O.Box 67, Hungary


Received 11 March 2004 Accepted as revised 17 May 2004

© 2004 Lippincott Williams & Wilkins, Inc.